Technology

GC Biopharma Corp. and HanmiPharm to Export Technology for New Fabry Disease Drug to U.S.-Based BioMarin for Up to 634.7 Billion Won

Secured 93.5 billion won in advance payments… 541.1 billion won in milestone payments, plus royalties Royalties Split 50-50 Between the Two Companies… A Milestone Achieved After Six Years of Joint Development Biomarine Secures Global Exclusive Rights Excluding South Korea… to Lead Follow-up Clinical Trials

KIM SAE-MI
2026-10-30 06:01:03
[E-Daily Reporter KIM SAE-MI ] GC Biopharma Corp. and HanmiPharm(128940)have licensed a Fabry disease drug candidate, jointly developed by the two companies, to BioMarin, a U.S.-based pharmaceutical company specializing in rare diseases, in a deal worth up to $475 million (approximately 634.7 billion won). This achievement comes approximately six years after the two companies began their joint development in 2020.

On the 29th (local time), U.S.-based BioMarin announced via its official website that it had signed a global exclusive technology transfer agreement with GC Biopharma Corp. and HanmiPharm for the Fabry disease drug candidate “HM15421/GC1134A.” (Source: Screenshot from BioMarin’s official website)

According to the biotech industry on the 30th, BioMarin announced on the 29th (local time) that it had signed a global exclusive licensing agreement with GC Biopharma Corp. and HanmiPharm for the Fabry disease drug candidate “HM15421/GC1134A (LA-GLA).”

The total value of the agreement is $475 million (634.7 billion won), comprising an upfront payment of $70 million (93.5 billion won) and milestone payments of up to $405 million (541.2 billion won) tied to development, approval, and commercialization milestones. If the product is successfully commercialized in the future, separate tiered royalties linked to net sales will also be paid.

HanmiPharm and Green Cross Corporation(006280)will split the technology fees from this agreement equally. Each company will receive an upfront payment of $35 million (46.8 billion won), and milestone payments based on the development, approval, and commercialization stages could total up to $202.5 million (270.6 billion won). Accordingly, the maximum total technology royalties that the two companies can each secure amount to $203.75 million (317.4 billion won).

Through this agreement, BioMarin has secured the exclusive rights to develop and commercialize HM15421/GC1134A worldwide, excluding South Korea. The company plans to solely manage subsequent clinical development, production, and international commercialization following the ongoing Phase 1/2 clinical trial. GC Biopharma Corp. and HanmiPharm will retain the commercialization rights in South Korea.

HM15421/GC1134A is a long-acting enzyme replacement therapy (ERT) designed to replenish the alpha-galactosidase A (a-Gal A) enzyme, which is deficient in patients with Fabry disease. Unlike existing intravenous administration methods, it is being developed for subcutaneous injection. The two companies aim to develop a treatment that can be administered subcutaneously once a month.

Fabry disease is a rare genetic disorder caused by a mutation in the GLA gene, which reduces the activity of a specific enzyme and leads to the accumulation of glycolipids in the body. It can cause damage to the kidneys, heart, and peripheral nervous system. Existing enzyme replacement therapy (ERT) treatments have the drawback of requiring intravenous injections primarily every two weeks.

GC Biopharma Corp. and HanmiPharm signed a joint development agreement in 2020 to develop next-generation drugs for the treatment of lysosomal storage disorders. Subsequently, in 2024, they received approval from the U.S. Food and Drug Administration (FDA) for their Phase 1/2 clinical trial protocol, and in January of last year, they also obtained approval for the Phase 1/2 clinical trial in South Korea. In May of the same year, they began administering the drug to the first patients.

HM15421/GC1134A was designated as an FDA Orphan Drug in 2024. According to BioMarin, nonclinical studies confirmed differentiated efficacy in indicators related to kidney function, vascular health, and the peripheral nervous system.

Through this technology acquisition, BioMarin plans to expand its portfolio of Fabry disease treatments. Previously, in April, BioMarin acquired U.S.-based Amicure Therapeutics for approximately $4.8 billion (about 6.4128 trillion won), securing the oral Fabry disease treatment “Galafold” (active ingredient: migalastat).

Galafold is a treatment for Fabry disease patients with specific genetic mutations. BioMarin expects that if HM15421/GC1134A is successfully commercialized in the future, it will expand treatment options to include patients with genetic mutations for whom Galafold is not suitable.

Alexander Hardy, CEO of BioMarin, said, "This agreement, following the acquisition of Amicus earlier this year, demonstrates our commitment to developing treatments for patients with Fabry disease," adding, "HM15421/GC1134A has the potential to serve as a new treatment modality for Fabry disease and could broaden treatment opportunities for patients with genetic mutations that make them unsuitable for Galafold therapy."

Economy

Corporation

IT·Science

Economy

LGELECTRONICS’ Tennessee Plant Produces 10 Million Washing Machines… Leading the Way to No. 1 in North America

LGELECTRONICS’ Tennessee plant has surpassed 10 million units in cumulative production of laundry appliances. Since establishing its local production system, the company has risen to the top spot in b…
2026-11-15 14:44:40

Corporation

“Stop Personal Data Leaks”… Retail Sector on High Alert to Protect Customer Information

The retail industry is successively overhauling its organizational structures and management systems to protect personal information. As the volume of customer data handled by retail companies has inc…
2026-11-15 16:38:03

IT·Science

'Summoners War' Champion Garin: Com2uS Corporation' 'SWC2026' Concludes to Great Success

Com2uS Corporation(078340)’s global esports tournament, the “Summoners War World Arena Championship 2026 (SWC2026),” concluded successfully with a sold-out crowd. In this tournament, TARS, representin…
2026-11-15 19:48:46